On each fresh manual launch, the GUI automatically uploads only the allowlisted project files using GitHub CLI, then replaces its own process with a restarted copy. The old GUI closes because ...

Python is one of the most popular programming languages today, widely praised for its simplicity and versatility. Whether you’re a beginner dipping your toes into coding or an experienced developer ...

A new experimental drug may offer hope for pancreatic cancer patients. One of deadliest types of cancer in the United States, an estimated 52,740 Americans will die from the disease this year, ...

Abstract: BrachyUtils is a modular Python framework designed to streamline reproducible research in high dose rate (HDR) brachytherapy. It addresses limitations in complex clinical workflows that ...

Current therapies offer limited benefit for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is the key driver of PDAC, with ...

IT skills are becoming essential for almost every modern job, especially as companies shift toward cloud systems, automation, and data-driven work. Beginner tech skills like Python scripting, SQL ...

New clinical trial data show KRAS-blocking drugs may significantly improve survival for the disease. “I think this is truly an earth-shattering moment in pancreatic cancer.” Daraxonrasib, an ...

Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Former Senator Ben Sasse has become an unlikely public face of a drug that researchers are ...

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.